Pharmacokinetics and glucodynamics of insulin lispro

Drugs of Today

Volumn 34, Issue SUPPL. C, 1998, Pages 23-36

  Heinemann, L ^a   Woodworth, J ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; GLUCOSE; HUMAN INSULIN; HUMULIN U; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; NEUTRAL INSULIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG POTENCY; GLUCOSE BLOOD LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031836628     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. The Diabetes Control and Complications Trial Research Group [DCCT]. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993, 329: 977-86.
2. Chance, R.E., Frank, B.H., Radziuk, J.M., DiMarchi, R.D. Discovery and development of insulin lispro. Drugs Today 1998, 34 (Suppl. C): 1-9.
3. Heinemann, L., Starke, A.A.R., Hohmann, A., Berger, M. Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal. Horm Metab Res 1992, Suppl. 26: 137-9.
4. Jørgensen, L.N., Nielsen F.S. Timing of pre-meal insulins in diabetic patients on a multiple daily injection regimen. A questionnaire study. Diabetologia 1990. 33 (Suppl. 1): A116.
5. Heinemann, L. Do insulin-treated diabetic patients use an injection-meal interval in daily life? Diabetes Med 1995, 12: 449-50.
6. Heinemann, L., Overmann, H., Mühlhauser, I. How do patients with diabetes mellitus type I handle the injection-meal interval in daily life? Diabetes 1997, 46 (Supp 1): 339A.
7. Vora, J.P., Owens, D.R., Dolben, J. et al. Recombinant DNA derived monomeric insulin analogue: Comparison with soluble human insulin in normal subjects. Br Med J 1988, 297: 1236-9.
8. B28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care 1991, 14: 571-7.
9. Heinemann, L., Starke, A.A.R., Heding, L., Jensen, I., Berger, M. Action profiles of fast onset insulin analogues. Diabetologia 1990, 33: 384-6.
10. Heinemann, L., Heise, T., JØrgensen, L.N., Starke, A.A.R. Action profile of the rapid acting insulin analogue: Human insulin B28Asp. Diabetes Med 1993, 10: 535-9.
11. Howey, D.C., Hooper, S.A., Bowsher, R.R. [Lys(B28), Pro(B29)]-human insulin: An equipotent analog of human insulin with rapid onset and short duration of action. Diabetes 1991, 40 (Suppl. 1): 423 A.
12. Howey, D.C., Bowsher, R.R., Brunelle, R.L., Woodworth, J.R. [Lys(B28), Pro(B29)]-human insulin: A rapidly absorbed analogue of human insulin. Diabetes 1994, 43: 396-402.
13. Woodworth, J., Howey, D., Bowsher, R., Lutz, S., Santa, P., Brady, P. [Lys(B28), Pro(B29)] human insulin (K): Dose-ranging vs. Humulin R (H). Diabetes 1993, 42 (Suppl. 1): 54A.
14. Data on file. Lilly Research Laboratories.
15. Clore, J., Woodworth, J.R., Cerimele, B.J., Blackard, W.G., Kurtz, D. Mixing insulin lispro (LP) with ultralente (U) insulin does not result in decreased or delayed LP absorption. Diabetes 1997, 46 (Suppl. 1): 150A.
16. Joseph, S., Burakowska, A., Wood-worth, J.R. et al. The action profile of lispro is not blunted by mixing in the syringe with NPH-insulin. Diabetes 1997, 46 (Suppl. 1): 166A.
17. Torlone, E., Pampanelli, S., Lalli, C. et al. Effects of the short-acting insulin analog [Lys(B28). Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 1996, 19: 945-52.
18. Anderson, J.H. Jr., Koivisto, V.A. Clinical studies on insulin lispro. Drugs Today 1998, 34 (Suppl. C): 37-50.
19. ter Braak, E.W., Woodworth, J.R., Bianchi, R. et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996, 19: 1437-40.
20. Jacobs, M.A.J.M., Salobir, B., Popp-Snijders, C., Ader, H., Heine, R.J. Counterregulatory hormone responses and symptoms during hypoglycaemia induced by porcine, human regular insulin, and Lys(B28), Pro(B29) human insulin analogue (insulin lispro) in healthy male volunteers. Diabetes Med 1997, 14: 248-57.
21. Torlone, E., Fanelli, C., Rambotti, A.M. et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 1994, 37: 713-20.
22. Kang, S., Owens, D.R., Vora, J.P., Brange, J. Comparison of insulin analogue B9AspB27Glu and soluble human insulin in insulin-treated diabetes. Lancet 1990, 335: 303-6.
23. Heinemann, L., Heise, T., Wahl, L.Ch. et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: Using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabetes Med 1996, 13: 625-9.
24. Bruttomesso, D., Pianta, A., Valerio, A., Tadiotto, F., Lavagnini, T., Del Prato, S. Fast acting insulin analog (lispro) improves glucose tolerance of NIDDM by inhibiting hepatic glucose production. Diabetes 1996, 45 (Suppl. 2): 140A.
25. Jacobs, M.A.J.M., Keulen, E.T.P., Kanc, K. et. al. Metabolic efficacy of preprandial administration of Lys(B28)Pro(B29) human insulin analog in IDDM patients. Diabetes Care 1997, 20(8): 1279-86.
26. Antsiferov, M., Woodworth, J.R., Mayorov, A., Ristic, S., Dedov, I. Within patient variability in postprandial glucose excursion with lispro insulin analog compared with regular insulin. Diabetologia 1995, 38 (Suppl. 1): A190.
27. Vignati, L., Anderson, J.H., Iverson, P.W. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or noninsulin-dependent diabetes mellitus. Clin Ther 1997, 19: 1408-21.
28. Pampanelli, S., Torlone, E., Lalli, C. et al. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic β-cell function. Diabetes Care 1995, 18: 1452-9.
29. Howey, D.C., Bowsher, R.R., Brunelle, R.L. et al. [Lys(B28), Pro(B29)]-human insulin: Effect of injection time on post-prandial glycemia. Clin Pharmacol Ther 1995, 58: 459-69.
30. Schernthaner, G., Wein, W., Sandholzer, K., Equiluz-Bruck, S., Birkett, M. Postprandial use of insulin lispro: A new therapeutic option in the treatment of type I diabetic patients? Diabetologia 1996, 39 (Suppl. 1): A24.
31. Duckworth, W.C. Insulin degradation: Mechanisms, products, and significance. Endocrinol Rev 1988, 9: 319-45.
32. Hamel, F.G., Siford, G., Frank, B.H., Chance, R.E., Duckworth, W.C. B10-Asp insulin (B10), but not B28-Lys. B29-Pro insulin (Lyspro), is resistant to metabolism by hepatocytes and insulin degrading enzyme (IDE). Diabetes 1997, 46 (Suppl. 1): 204A.